Mobidiag Secures Additional Funding from Business Finland for Rapid Sepsis Diagnostic Test

ESPOO, Finland, January 07, 2020 – Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has been granted EUR 1.5 million ($1.65 million) additional funding from Business Finland (formerly Tekes) for the continued development of a rapid diagnostic test for sepsis using Mobidiag’s Novodiag platform. This additional funding has been secured as a result of strong progress in the development of the assay and the completion of key milestones by Mobidiag since the award of the first grant in May 2018. The new funding brings the total loan to EUR 3 million ($3.3 million).

Continue Reading

Mobidiag Symposium on Innovative Molecular Diagnostics to be held for Third year at RICAI Annual Meeting

PARIS, France, December 11th, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, will host a symposium at the 39th Interdisciplinary Meeting of Anti-Infectious Chemotherapy (RICAI) conference in Paris, from the 16th to 17th of December.

The RICAI conference is an annual meeting bringing together leading French clinicians and microbiologists (parasitologists, virologists, bacteriologists) and innovative commercial companies in diagnostics.

Continue Reading

Mobidiag Appoints Joseph Bernardo as Senior Strategic Advisor

ESPOO, Finland, December 10, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the appointment of Joseph E. Bernardo as Senior Strategic Advisor to the Company.

Mr. Bernardo has over twenty years of experience in the diagnostics industry including a significant tenure as a President at Thermo Fisher Scientific, working across a number of divisions including Clinical Next-Generation Sequencing and Oncology, Immuno-Diagnostics, Anatomic Pathology and Fisher HealthCare, the hospital laboratory distribution business of Thermo Fisher.

Continue Reading

Mobidiag signs new international agreements for distribution of its Amplidiag® and Novodiag® diagnostic solutions

Agreements signed in Poland, Ukraine, Romania and Israel, with more in discussions.

ESPOO, Finland, October 29th, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has signed new exclusive agreements with international partners for the distribution of its Amplidiag® and Novodiag® products in Europe and the Middle East.
Mobidiag has signed exclusive agreements for the distribution of Amplidiag® and Novodiag® with ALAB Ltd. for Poland and Ukraine, BIOgenetiX for Romania and Theranostica Ltd. for Israel.

Continue Reading

NEW! Novodiag® Stool Parasites, comprehensive and cost-effective molecular diagnostic test for detection of intestinal parasites

CE-IVD marking of Novodiag® Stool Parasites, the 4th molecular test on the automated system Novodiag®, for detection of the most common protozoan, helminths and microsporidia in one single test.

ESPOO, Finland, October 09, 2019 – Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the CE-IVD marking of the Novodiag® Stool Parasites test, a comprehensive and cost-effective molecular diagnostic test for the detection of intestinal parasites directly from stool samples.

Continue Reading

Novodiag® CarbaR+ featured in Biomedical Scientist magazine – Complete evaluation by Nottingham University Hospital QMC

The article features the successful evaluation of Novodiag® CarbaR+ conducted by Nottingham University Hospitals, NHS Trust, Clinical Microbiology, Queen’s Medical Centre.

Shova Sharma, Associate Practitioner & Experimental Lead of the evaluation and Su Sewaa, Deputy Service Manager of NUH QMC have recently evaluated the test and their results are featured in this month´s Biomedical Scientist issue. NUH Clinical Microbiology will be publishing poster of the evaluation in October 2019 at EMMD in the Netherlands.

Continue Reading

Mobidiag´s Novodiag® CarbaR+ test is one of the finalists at the International Medtech Insight Award 2019

Delighted to announce that Mobidiag´s Novodiag® CarbaR+ test has been shortlisted for Best Technological Innovation: Diagnostics at the 2019 Medtech Insight Awards.

“This Award will recognize the efforts of an individual, team, or company that developed an innovative medical device or diagnostic that makes significant contributions to advancing patient treatment. The judges will be looking for the product that represents the most innovative new approach to care by addressing an unmet clinical need; by changing the practice of health care to be more effective, efficient or less error-prone; or by expanding technology to new patient populations.”

Continue Reading

Mobidiag signs exclusive agreement with Pro Med Diagnostics for the distribution of Amplidiag® and Novodiag® diagnostic solutions in Africa

Agreement signed for South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya, Uganda

ESPOO, Finland, July 1st, 2019 Mobidiag Ltd. today announces that it has signed an exclusive agreement with Pro Med Diagnostics for the distribution of its Amplidiag® and Novodiag® products in African countries including South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya and Uganda.

Tuomas Tenkanen, CEO of Mobidiag, said “We are excited to further expand our commercial footprint into Africa, which represents a fast growing market for diagnostic products with enormous growth potential. We are focused on continuing to develop our distributor network as part of our strategy to make our IVD tests and instruments accessible to customers in centralized and decen

Continue Reading

Mobidiag announces launch of Automobi Molecular Diagnostics

FINLAND Espoo/CHINA, Zhengzhou, June 3 2019 – Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, today announces the launch of Automobi Molecular Diagnostics Co., Ltd (‘Automobi’), the joint venture (‘JV’) between Mobidiag and Autobio Diagnostics (‘Autobio’), one of the leading clinical diagnostics companies in China. Automobi is responsible for commercialising the Novodiag® platform and selected infectious disease assays in the Greater China territory.

Continue Reading